A new issue brief explores the coverage policies in Australia, Germany, and the United Kingdom for potentially life-extending—but expensive—medicines that may offer only modest benefits near the end of life. The costs of these drugs can stretch the budgets of payers as well as patients, an issue the United States will need to grapple with as health reform extends coverage to more Americans.
